AR054122A1 - Pirido[2,3-d]pirimidas utiles como inhibidores de hcv, y metodos para la preparacion de las mismas - Google Patents
Pirido[2,3-d]pirimidas utiles como inhibidores de hcv, y metodos para la preparacion de las mismasInfo
- Publication number
- AR054122A1 AR054122A1 ARP060101904A ARP060101904A AR054122A1 AR 054122 A1 AR054122 A1 AR 054122A1 AR P060101904 A ARP060101904 A AR P060101904A AR P060101904 A ARP060101904 A AR P060101904A AR 054122 A1 AR054122 A1 AR 054122A1
- Authority
- AR
- Argentina
- Prior art keywords
- preparation
- pyrimides
- pirido
- useful
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente se refiere al uso de pirido [2,3-d]pirimidinas como inhibidores de replicacion de HCV así como también a su empleo en composiciones farmacéuticas destinadas a tratar o combatir infecciones con HCV. Además, la presente se refiere a los compuestos de pirido[2,3-d]pirimidinas en sí mismos y a su uso como medicinas. La presente también se refiere a procesos para la preparacion de tales compuestos, a composiciones farmacéuticas que los comprenden, y a combinaciones de dichos compuestos con otros agentes anti-HCV.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68040505P | 2005-05-12 | 2005-05-12 | |
EP05106214 | 2005-07-07 | ||
EP06075855 | 2006-04-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR054122A1 true AR054122A1 (es) | 2007-06-06 |
Family
ID=37198763
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060101904A AR054122A1 (es) | 2005-05-12 | 2006-05-11 | Pirido[2,3-d]pirimidas utiles como inhibidores de hcv, y metodos para la preparacion de las mismas |
Country Status (20)
Country | Link |
---|---|
US (1) | US8022077B2 (es) |
EP (1) | EP1888580B1 (es) |
JP (1) | JP5464686B2 (es) |
KR (1) | KR20080007268A (es) |
CN (1) | CN101203515B (es) |
AR (1) | AR054122A1 (es) |
AT (1) | ATE459623T1 (es) |
AU (1) | AU2006245676B2 (es) |
BR (1) | BRPI0609098A2 (es) |
CA (1) | CA2608301C (es) |
DE (1) | DE602006012666D1 (es) |
DK (1) | DK1888580T3 (es) |
ES (1) | ES2341572T3 (es) |
IL (1) | IL186881A (es) |
MX (1) | MX2007014082A (es) |
RU (1) | RU2444522C2 (es) |
SI (1) | SI1888580T1 (es) |
TW (1) | TW200716631A (es) |
WO (1) | WO2006120252A2 (es) |
ZA (1) | ZA200709689B (es) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2577745C (en) * | 2004-09-30 | 2012-11-27 | Tibotec Pharmaceuticals Ltd. | Hcv inhibiting bi-cyclic pyrimidines |
DK1869037T3 (da) * | 2005-03-25 | 2011-10-24 | Tibotec Pharm Ltd | Heterobicykliske inhibitorer af HVC |
AR056347A1 (es) | 2005-05-12 | 2007-10-03 | Tibotec Pharm Ltd | Uso de compuestos de pteridina para fabricar medicamentos y composiciones farmaceuticas |
WO2007081517A2 (en) * | 2005-12-21 | 2007-07-19 | Abbott Laboratories | Anti-viral compounds |
RU2441010C2 (ru) * | 2005-12-21 | 2012-01-27 | Эбботт Лэборетриз | Противовирусные соединения |
CN102702194A (zh) | 2005-12-21 | 2012-10-03 | 雅培制药有限公司 | 抗病毒化合物 |
WO2007076034A2 (en) * | 2005-12-21 | 2007-07-05 | Abbott Laboratories | Anti-viral compounds |
TWI399380B (zh) | 2006-12-20 | 2013-06-21 | Abbott Lab | 抗病毒化合物 |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
EP2376088B1 (en) | 2008-12-23 | 2017-02-22 | Gilead Pharmasset LLC | 6-O-Substituted-2-amino-purine nucleoside phosphoramidates |
US8551973B2 (en) | 2008-12-23 | 2013-10-08 | Gilead Pharmasset Llc | Nucleoside analogs |
EA019295B1 (ru) | 2008-12-23 | 2014-02-28 | Джилид Фармассет, Ллс. | Соединения пуриновых нуклеозидов и способ их получения |
TWI576352B (zh) | 2009-05-20 | 2017-04-01 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
KR101579079B1 (ko) * | 2010-03-10 | 2015-12-21 | 애브비 바하마스 리미티드 | 고체 조성물 |
JP2013527145A (ja) | 2010-03-31 | 2013-06-27 | ギリード・ファーマセット・エルエルシー | リン含有活性化剤の立体選択的合成 |
PL3290428T3 (pl) | 2010-03-31 | 2022-02-07 | Gilead Pharmasset Llc | Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu |
EP2609923B1 (en) | 2010-03-31 | 2017-05-24 | Gilead Pharmasset LLC | Process for the crystallisation of (s)-isopropyl 2-(((s)-(perfluorophenoxy)(phenoxy)phosphoryl)amino)propanoate |
AR084044A1 (es) | 2010-11-30 | 2013-04-17 | Pharmasset Inc | Compuestos 2’-espiro-nucleosidos |
SI3330257T1 (sl) | 2011-04-08 | 2020-07-31 | Janssen Sciences Ireland Unlimited Company | Derivati pirimidina za zdravljenje virusnih okužb |
ES2690082T3 (es) | 2011-11-09 | 2018-11-19 | Janssen Sciences Ireland Uc | Derivados de purina para el tratamiento de infecciones virales |
US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
MX360718B (es) | 2012-07-13 | 2018-11-13 | Janssen Sciences Ireland Uc | Purinas macrocíclicas para el tratamiento de infecciones víricas. |
US9499549B2 (en) | 2012-10-10 | 2016-11-22 | Janssen Sciences Ireland Uc | Pyrrolo[3,2-]pyrimidine derivatives for the treatment of viral infections and other diseases |
JP6297055B2 (ja) | 2012-11-16 | 2018-03-20 | ヤンセン・サイエンシズ・アイルランド・ユーシー | ウイルス感染症の治療のための複素環置換2−アミノ−キナゾリン誘導体 |
KR102300861B1 (ko) | 2013-02-21 | 2021-09-10 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 바이러스 감염의 치료를 위한 2-아미노피리미딘 유도체 |
JP6336036B2 (ja) | 2013-03-29 | 2018-06-06 | ヤンセン・サイエンシズ・アイルランド・ユーシー | ウイルス感染治療のための大環状デアザプリノン |
SG11201509520QA (en) | 2013-05-24 | 2015-12-30 | Janssen Sciences Ireland Uc | Pyridone derivatives for the treatment of viral infections and further diseases |
WO2014207082A1 (en) | 2013-06-27 | 2014-12-31 | Janssen R&D Ireland | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases |
MY179503A (en) | 2013-07-30 | 2020-11-09 | Janssen Sciences Ireland Uc | Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections |
PL3650014T3 (pl) | 2013-08-27 | 2022-01-31 | Gilead Pharmasset Llc | Preparat złożony dwóch związków przeciwwirusowych |
US10030004B2 (en) | 2014-01-01 | 2018-07-24 | Medivation Technologies Llc | Compounds and methods of use |
EP2905024A1 (en) | 2014-02-07 | 2015-08-12 | Institut Quimic De Sarriá Cets, Fundació Privada | Pyrido[2,3-d]pyrimidine-7(8H)-one derivatives for the treatment of infections caused by Flaviviridae |
JP7171444B2 (ja) | 2016-07-01 | 2022-11-15 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | ウイルス感染治療用のジヒドロピラノピリミジン |
CN109790154B (zh) | 2016-09-29 | 2023-06-23 | 爱尔兰詹森科学公司 | 用于治疗病毒感染和另外的疾病的嘧啶前药 |
TW202415645A (zh) | 2018-03-01 | 2024-04-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | 2,4-二胺基喹唑啉衍生物及其醫學用途 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE789496A (es) | 1971-10-05 | 1973-03-29 | S M B Anciens Ets J Muelberger | |
IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
RU2340611C2 (ru) * | 2000-09-15 | 2008-12-10 | Вертекс Фармасьютикалз Инкорпорейтед | Производные пиразола, используемые в качестве ингибиторов протеинкиназы |
EP1465900B1 (en) | 2002-01-10 | 2008-05-14 | Bayer HealthCare AG | Rho-kinase inhibitors |
JP2003321472A (ja) | 2002-02-26 | 2003-11-11 | Takeda Chem Ind Ltd | Grk阻害剤 |
WO2003097615A1 (en) * | 2002-05-17 | 2003-11-27 | Scios, Inc. | TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-β INHIBITORS |
AU2003260072A1 (en) | 2002-08-27 | 2004-03-19 | Bristol-Myers Squibb Company | Antagonists of chemokine receptors |
US7148226B2 (en) * | 2003-02-21 | 2006-12-12 | Agouron Pharmaceuticals, Inc. | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same |
US7232824B2 (en) * | 2003-09-30 | 2007-06-19 | Scios, Inc. | Quinazoline derivatives as medicaments |
WO2006105063A1 (en) * | 2005-03-25 | 2006-10-05 | Scios Inc. | Heterobicylic inhibitors of tgfbeta |
DK1869037T3 (da) * | 2005-03-25 | 2011-10-24 | Tibotec Pharm Ltd | Heterobicykliske inhibitorer af HVC |
-
2006
- 2006-05-11 TW TW095116638A patent/TW200716631A/zh unknown
- 2006-05-11 AR ARP060101904A patent/AR054122A1/es unknown
- 2006-05-12 WO PCT/EP2006/062290 patent/WO2006120252A2/en active Application Filing
- 2006-05-12 KR KR1020077027718A patent/KR20080007268A/ko not_active Application Discontinuation
- 2006-05-12 AT AT06763142T patent/ATE459623T1/de not_active IP Right Cessation
- 2006-05-12 AU AU2006245676A patent/AU2006245676B2/en not_active Ceased
- 2006-05-12 MX MX2007014082A patent/MX2007014082A/es active IP Right Grant
- 2006-05-12 ES ES06763142T patent/ES2341572T3/es active Active
- 2006-05-12 US US11/914,044 patent/US8022077B2/en not_active Expired - Fee Related
- 2006-05-12 JP JP2008510594A patent/JP5464686B2/ja not_active Expired - Fee Related
- 2006-05-12 CA CA2608301A patent/CA2608301C/en not_active Expired - Fee Related
- 2006-05-12 EP EP06763142A patent/EP1888580B1/en active Active
- 2006-05-12 CN CN200680016369.5A patent/CN101203515B/zh not_active Expired - Fee Related
- 2006-05-12 DK DK06763142.4T patent/DK1888580T3/da active
- 2006-05-12 RU RU2007146173/04A patent/RU2444522C2/ru not_active IP Right Cessation
- 2006-05-12 SI SI200630653T patent/SI1888580T1/sl unknown
- 2006-05-12 BR BRPI0609098-2A patent/BRPI0609098A2/pt not_active Application Discontinuation
- 2006-05-12 DE DE602006012666T patent/DE602006012666D1/de active Active
-
2007
- 2007-10-24 IL IL186881A patent/IL186881A/en not_active IP Right Cessation
- 2007-11-09 ZA ZA200709689A patent/ZA200709689B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
CA2608301C (en) | 2014-04-22 |
WO2006120252A2 (en) | 2006-11-16 |
CN101203515B (zh) | 2014-02-26 |
ATE459623T1 (de) | 2010-03-15 |
CA2608301A1 (en) | 2006-11-16 |
MX2007014082A (es) | 2008-04-17 |
BRPI0609098A2 (pt) | 2010-02-17 |
EP1888580B1 (en) | 2010-03-03 |
RU2007146173A (ru) | 2009-06-20 |
KR20080007268A (ko) | 2008-01-17 |
RU2444522C2 (ru) | 2012-03-10 |
ZA200709689B (en) | 2009-07-29 |
AU2006245676B2 (en) | 2012-08-02 |
SI1888580T1 (sl) | 2010-06-30 |
JP2008540494A (ja) | 2008-11-20 |
ES2341572T3 (es) | 2010-06-22 |
US20090131460A1 (en) | 2009-05-21 |
DK1888580T3 (da) | 2010-06-14 |
AU2006245676A1 (en) | 2006-11-16 |
EP1888580A2 (en) | 2008-02-20 |
TW200716631A (en) | 2007-05-01 |
JP5464686B2 (ja) | 2014-04-09 |
IL186881A0 (en) | 2008-02-09 |
CN101203515A (zh) | 2008-06-18 |
WO2006120252A3 (en) | 2007-02-22 |
DE602006012666D1 (de) | 2010-04-15 |
IL186881A (en) | 2015-06-30 |
US8022077B2 (en) | 2011-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR054122A1 (es) | Pirido[2,3-d]pirimidas utiles como inhibidores de hcv, y metodos para la preparacion de las mismas | |
AR047928A1 (es) | Derivados de tetrahidropiridoindol | |
BRPI0516751A (pt) | pirimidinas bicìclicas que inibem hcv | |
UY31673A1 (es) | "derivados heterocíclicos de urea y métodos de uso de los mismos-211" | |
CO6390082A2 (es) | Compuestos organicos | |
BRPI0813237B8 (pt) | composto, método para preparar o composto, medicamento, e, uso do composto | |
CL2006001266A1 (es) | Formas solidas cristalinas i, ii, iii, iv y v de tigeciclina; procedimiento de preparacion de las formas cristalinas ii, iv y v; composicion farmaceutica que comprende las formas cristalinas; y su uso para tratar infecciones bacterianas. | |
WO2007026024A3 (en) | Benzodiazepines as hcv inhibitors | |
ECSP099451A (es) | Compuestos de urea policíclicos antibacterianos | |
CR20150199A (es) | Análogos de 2´-cloro nucleósido para infección por vhc | |
ECSP077316A (es) | Compuestos imidazo-3-il-amina bicíclicos sustituidos | |
BR112015014333A8 (pt) | compostos antivirais, seu uso e composição farmacêutica que os compreende | |
CL2007003187A1 (es) | Compuestos derivados de bencil-benzonitrilo sustituido con glucopiranosilo y sus sales; procedimiento de preparacion; compuestos intermediarios; proceso para preparar los compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de | |
CL2008001345A1 (es) | Compuestos derivados de imidazo[1,2-b]piridazinas, inhibidores de cinasa; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende; su proceso de preparacion; y su uso en enfermedades hiperproliferativas, inflamatorias, alergicas y obstructivas de las vias respiratorias, entre otras. | |
NO20091258L (no) | Entantiomerisk rene fosfoindoler as HIV inhibitorer | |
CL2007001166A1 (es) | Compuestos derivados de pirimidina condensada, inhibidores de pi3-quinasa; procesos para preparar los compuestos; composicion farmaceutica que los comprende; uso de los compuestos en la preparacion de medicamentos; proceso para preparar la composicion farmaceutica; y kit que incluye a la composicion farmaceutica | |
CL2011000729A1 (es) | Compuestos derivados de metanopirazolo[3,4-e][1,3]diazepin; procedimiento de preparacion; composicion farmaceutica que los comprende; y su uso en el tratamiento de infecciones bacterianas. | |
CL2007002856A1 (es) | Compuestos derivados de pirazolo(1,5)pirimidina; composicion farmaceutica qu lo comprende;y su uso para tratar el cancer. | |
AR057148A1 (es) | Combinaciones farmacologicas para el tratamiento de enfermedades de las vias respiratorias | |
AR071120A1 (es) | Derivados de diosmetina, su procedimiento de preparacion, las composiciones farmaceuticas que los contienen y su uso en el tratamiento de las enfermedades venosas cronicas. | |
UY30544A1 (es) | Compuestos de pirrolo-piperidina y sales farmacéuticametne aceptables de los mismos, procesos de fabricacion, composiciones y aplicaciones | |
GT200600369A (es) | Proceso | |
UY31864A (es) | Derivados de urea hetericíclica y métodos de uso de los mismos-332 | |
DK1869038T3 (da) | Substituerede 5,6,7,8-tetrahydro-imidazol[1,2-a]pyridin-2-ylamin-forbindelser og deres anvendelse til fremstilling af lægemidler | |
CL2008002082A1 (es) | Compuestos derivados de 6-fenil-1h-imidazo[4,5-c]piridina-4-carbonitrilo, inhibidores de catepsina s y catepsina k; composicion farmaceutica; y uso en el tratamiento de osteoporosis, aterosclerosis, inflamacion, entre otras enfermedades. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |